01 9Tysabri
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 1,946
2019 Revenue in Millions : 1,892
Growth (%) : 3
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 2,063
2020 Revenue in Millions : 1,946
Growth (%) : 6
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 2,031
2021 Revenue in Millions : 2,063
Growth (%) : -2
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 1,877
2022 Revenue in Millions : 2,031
Growth (%) : -8
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,960
2014 Revenue in Millions : 1,886
Growth (%) : -4%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 1,864
2017 Revenue in Millions : 1,973
Growth (%) : -6%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 1,973
2016 Revenue in Millions : 1,964
Growth (%) : 0.5
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 1,964
2015 Revenue in Millions : 1,886
Growth (%) : 4
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 1,892
2018 Revenue in Millions : 1,864
Growth (%) : 2
LOOKING FOR A SUPPLIER?